Dissecting the Clinical Characteristics and Treatment Outcomes Correlates of KRAS G12C-Mutated Non-Small Cell Lung Cancer
Yawan Jing,Ruixin Cheng,Hao Zeng,Qin Huang,Dongyu He,Jiayi Sun,Panwen Tian,Yalun Li
DOI: https://doi.org/10.2147/ijgm.s484435
IF: 2.145
2024-10-04
International Journal of General Medicine
Abstract:Yawan Jing, 1, 2 Ruixin Cheng, 3 Hao Zeng, 1 Qin Huang, 1 Dongyu He, 1 Jiayi Sun, 1 Panwen Tian, 1, 4 Yalun Li 1, 4 1 Department of Pulmonary and Critical Care Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, Institute of Respiratory Health and Multimorbidity, Institute of Respiratory Health, Frontiers Science Center for Disease-Related Molecular Network, Precision Medicine Center/Precision Medicine Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Chengdu, Sichuan, People's Republic of China; 2 Department of Gerontology and Geriatrics, Tibet Autonomous Region People's Hospital, Lhasa, Tibet Autonomous Region, People's Republic of China; 3 Department of Radiation Oncology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong, 510080, People's Republic of China; 4 Lung Cancer Center/Lung Cancer Institute, West China Hospital, Sichuan University, Chengdu, Sichuan, People's Republic of China Correspondence: Yalun Li; Panwen Tian, Department of Pulmonary and Critical Care Medicine, West China Hospital, Sichuan University, No. 37 GuoXue Alley, Chengdu, Sichuan Province, 610041, People's Republic of China, Tel/Fax +86 28 85423660, Email ; Background: KRAS mutation is one of the most common driver oncogenes in non-small cell lung cancer (NSCLC), and the most common mutation subtype is G12C . However, there is still a lack of efficacy and prognosis data related to immunotherapy, which hinders the promotion of new strategies. Methods: Clinical characteristics and treatment outcomes were collected and analyzed for patients with NSCLC harboring KRAS mutations at West China Hospital of Sichuan University from June 2013 to March 2023. Results: Among the 231 patients with KRAS -mutated NSCLC, 29.4% had KRAS G12C mutations. Compared to the KRAS non-G12C NSCLC group, the KRAS G12C NSCLC group had a greater number of pack-years. The programmed death ligand 1 expression and the proportion of patients with a high tumor mutational burden were not significantly different between the two groups. Similar patterns of TP53, STK11 , and CDKN2A mutations were observed between KRAS G12C and KRAS non-G12C NSCLC groups. The median progression-free survival (PFS) (8.4 vs 7.0 months, p=0.100) and overall survival (OS) (12.1 vs 18.1 months, p=0.590) were not statistically different between KRAS G12C and KRAS non-G12C . Compared to patients with KRAS G12C NSCLC who did not receive immunotherapy, patients who received immunotherapy had a better objective response rate (46.2% vs 0%, p=0.002), PFS (12.2 vs 7.5 months, p=0.087) and OS (49.9 vs 11.1 months, p=0.12). Conclusion: Patients with KRAS G12C were more likely to be smokers. Advanced KRAS G12C NSCLC patients who received immunotherapy had a better ORR than those who did not, suggesting that patients with G12C mutations are more likely to benefit from immunotherapy. Keywords: non-small cell lung cancer, KRAS G12C mutation, KRAS mutation, immunotherapy, overall survival Lung cancer is the leading cause of cancer-related mortality, accounting for more than 1.8 million deaths a year, and non-small cell lung cancer (NSCLC) is the most common subtype. 1–3 KRAS mutations are present in 25–39% of non-squamous NSCLCs. 4–6 The KRAS G12C mutation is present in approximately 40–46% of patients with KRAS -mutant NSCLC and 13–16% of those with lung adenocarcinoma 6 and is the most common KRAS mutation in lung cancer. 7,8 KRAS G12C inhibitors represent a significant advancement in the field of targeted therapies for NSCLC. 9–18 According to the latest version of the National Comprehensive Cancer Network (NCCN) clinical practice guidelines, the optimal first-line therapy for advanced KRAS -mutant NSCLC still consists of programmed cell death (ligand) 1 blockade alone or in combination with platinum-based chemotherapy, 19 and resistance to KRAS inhibitor monotherapy will eventually develop. 6,20,21 Given that drug combination therapy is currently a clinically recognized strategy for overcoming resistance to KRAS G12C inhibitors, combining KRAS G12C -targeted drugs with other drugs (such as immunotherapy and chemotherapy) may be one of the key strategies for overcoming drug resistance. The application of these compounds in clinical pract -Abstract Truncated-
medicine, general & internal